natgillin/translations-raw huggingface dataset:
Irbesartan Winthrop at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Na splošno zagotavlja odmerek 150 mg zdravila Irbesartan Winthrop enkrat na dan boljši 24 urni nadzor krvnega tlaka kot 75 mg.
In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan Winthrop can be increased to 300 mg, or other anti-hypertensive agents can be added.
Pri bolnikih, kjer enkratni dnevni odmerek 150 mg zdravila Irbesartan Winthrop ne zadošča za nadzor krvnega tlaka, se lahko odmerek poveča na 300 mg ali uvede dodatni antihipertenziv.
In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Irbesartan Winthrop (see section 4.5).
In sicer, se je pri dodatni uvedbi diuretika, kot je hidroklorotiazid pokazal sinergistični učinek z zdravilom Irbesartan Winthrop (glejte poglavje 4. 5).
The demonstration of renal benefit of Irbesartan Winthrop in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see section 5.1).
Koristi zdravljenja z zdravilom Irbesartan Winthrop za ledvice pri bolnikih z visokim krvnim tlakom z diabetesom tipa 2 so pokazale študije, kjer so irbesartan uporabljali dodatno z drugimi antihipertenzivi, potrebnimi za doseganje ciljnega krvnega tlaka (glejte poglavje 5. 1).
Intravascular volume depletion: volume and/ or sodium depletion should be corrected prior to administration of Irbesartan Winthrop.
Zmanjšan intravaskularni volumen: pred uporabo zdravila Irbesartan Winthrop je treba korigirati zmanjšani volumen krvi in/ ali pomanjkanje natrija.
Such conditions should be corrected before the administration of Irbesartan Winthrop.
Ta stanja se mora korigirati, preden se uporabi zdravilo Irbesartan Winthrop.
While this is not documented with Irbesartan Winthrop, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Čeprav to za zdravilo Irbesartan Winthrop ni dokazano, je treba podobne učinke pričakovati pri antagonistih receptorjev za angiotenzin II.
Renal impairment and kidney transplantation: when Irbesartan Winthrop is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
Ledvična okvara in presaditev ledvic: pri dajanju zdravila Irbesartan Winthrop bolnikom s prizadeto ledvično funkcijo se priporoča redno nadzorovanje ravni kalija in kreatinina v serumu.
There is no experience regarding the administration of Irbesartan Winthrop in patients with a recent kidney transplantation.
Glede uporabe zdravila Irbesartan Winthrop pri bolnikih po nedavni presaditvi ledvic ni nobenih izkušenj.
Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Irbesartan Winthrop, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/ or heart failure.
Hiperkaliemija: kot pri drugih zdravilih, ki vplivajo na sistem renin- angiotenzin- aldosteron, se lahko tudi med zdravljenjem z zdravilom Irbesartan Winthrop pojavi hiperkaliemija, zlasti ob prisotnosti ledvične okvare, izrazite proteinurije zaradi diabetične ledvične bolezni in/ ali odpovedi srca.
Lithium: the combination of lithium and Irbesartan Winthrop is not recommended (see section 4.5).
Litij: sočasna uporaba zdravila Irbesartan Winthrop in litija ni priporočljiva (glejte poglavje 4. 5).
Therefore, the use of Irbesartan Winthrop is not recommended.
Zato uporaba zdravila Irbesartan Winthrop ni priporočljiva.
Diuretics and other antihypertensive agents: other antihypertensive agents may increase the hypotensive effects of irbesartan; however Irbesartan Winthrop has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Diuretiki in drugi antihipertenzivi: drugi antihipertenzivi lahko povečajo hipotenzivni učinek irbesartana; vendar pa so zdravilo Irbesartan Winthrop varno uporabljali z drugimi antihipertenzivi, kot so zaviralci adrenergičnih receptorjev beta, zaviralci kalcijevih kanalčkov z dolgotrajnim delovanjem in tiazidnimi diuretiki.
Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Irbesartan Winthrop (see section 4.4).
Predhodno zdravljenje z visokimi odmerki diuretikov lahko povzroči zmanjšanje volumna in tveganje za hipotenzijo ob uvedbi zdravljenja z zdravilom Irbesartan Winthrop (glejte poglavje 4. 4).
Irbesartan Winthrop is contraindicated (see section 4.3) during lactation.
Dojenje: med dojenjem je zdravilo Irbesartan Winthrop kontraindicirano (glejte poglavje 4. 3).
No specific information is available on the treatment of overdose with Irbesartan Winthrop.
Specifični podatki o zdravljenju predoziranja z zdravilom Irbesartan Winthrop niso na voljo.
The blood pressure lowering effect of Irbesartan Winthrop is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy.
Učinek zdravila Irbesartan Winthrop na znižanje krvnega tlaka je viden po 1- 2 tednih, največji učinek pa nastopi 4- 6 tednov po začetku zdravljenja.
The efficacy of Irbesartan Winthrop is not influenced by age or gender.
Spol in starost ne vplivata na učinkovitost zdravila Irbesartan Winthrop.
IDNT was a double blind, controlled, morbidity and mortality trial comparing Irbesartan Winthrop, amlodipine and placebo.
IDNT je bilo dvojno slepo, kontrolirano preskušanje vpliva zdravila Irbesartan Winthrop na obolevnost in smrtnost v primerjavi z amlodipinom in placebom.
In 1,715 hypertensive patients with type 2 diabetes, proteinuria ≥ 900 mg/ day and serum creatinine ranging from 1.0-3.0 mg/ dl, the long-term effects (mean 2.6 years) of Irbesartan Winthrop on the progression of renal disease and all-cause mortality were examined.
Pri 1. 715 bolnikih z visokim krvnim tlakom z diabetesom tipa 2, proteinurijo ≥900 mg/ dan in serumskim kreatininom 1, 0- 3, 0 mg/ dl, so raziskovali dolgotrajne učinke zdravila Irbesartan Winthrop (povprečje 2, 6 let) na napredovanje ledvične bolezni in na celokupno smrtnost.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Irbesartan Winthrop, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Bolnikom so postopoma povečevali odmerek zdravila Irbesartan Winthrop od 75 mg do vzdrževalnega odmerka 300 mg, odmerek amlodipina od 2, 5 do 10 mg, oziroma placeba, kot so ga prenesli.
Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively.
Irbesartan je pomembno znižal tveganje za primarno povezan
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
8 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
When the individual components of the
Približno 33% bolnikov v skupini z irbesartanom je doseglo primarno povezan ledvični izid v primerjavi s 39% pri placebu in 41% v skupini z amlodipinom [20% relativno zmanjšanje tveganja v primerjavi s placebom (p = 0, 024) in 23% relativno zmanjšanje tveganja v primerjavi z amlodipinom (p = 0, 006)].
8 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
The study examined the long-term effects (2 years) of Irbesartan Winthrop on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) > 300 mg/ day, and an increase in UAER of at least 30% from baseline).
V raziskavi so proučevali dolgotrajne učinke (2 leti) zdravila Irbesartan Winthrop na napredovanje v klinično proteinurijo (hitrost izločanja albuminov z urinom - “ urinary albumin excretion rate ” - UAER > 300 mg/ dan in povečanje UAER- a najmanj za 30% začetne vrednosti).
The major circulating metabolite is irbesartan glucuronide (approximately 6%).
Po peroralni ali intravenski uporabi 14C irbesartana, prispeva 80- 85% radioaktivnosti v plazemskem obtoku nespremenjeni irbesartan.
In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.
Glavni metabolit v obtoku je irbesartan glukuronid (približno 6%).
Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen.
Ravnotežne koncentracije v plazmi so dosežene v 3 dneh po začetku enkrat- dnevnega režima
9 However the terminal half-life was not significantly altered.
Vendar pa ni bilo pomembnih sprememb končnega razpolovnega časa.
Microcrystalline cellulose Croscarmellose sodium Lactose monohydrate Magnesium stearate Colloidal hydrated silica Pregelatinised maize starch Poloxamer 188
mikrokristalna celuloza premreženi natrijev karmelozat laktoza monohidrat magnezijev stearat
Irbesartan Winthrop 150 mg tablets.
Irbesartan Winthrop 150 mg tablete
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
18 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
18 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
19 However the terminal half-life was not significantly altered.
Vendar pa ni bilo pomembnih sprememb končnega razpolovnega časa.
20 6.2 Incompatibilities
6. 2 Inkompatibilnosti
Irbesartan Winthrop 300 mg tablets.
Irbesartan Winthrop 300 mg tablete
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
28 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
28 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
29 However the terminal half-life was not significantly altered.
Vendar pa ni bilo pomembnih sprememb končnega razpolovnega časa.
Irbesartan Winthrop 75 mg film-coated tablets.
Irbesartan Winthrop 75 mg filmsko obložene tablete
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
38 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
38 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Hypromellose Silicon dioxide Magnesium stearate.
Jedro tablete: laktoza monohidrat mikrokristalna celuloza premreženi natrijev karmelozat hipromeloza
40 Film-coating:
40 silicijev dioksid magnezijev stearat
Irbesartan Winthrop 150 mg film-coated tablets.
Irbesartan Winthrop 150 mg filmsko obložene tablete
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
49 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
49 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
51 Film-coating:
51 silicijev dioksid magnezijev stearat
Irbesartan Winthrop 300 mg film-coated tablets.
Irbesartan Winthrop 300 mg filmsko obložene tablete
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
60 izid podvojitve serumskega kreatinina, zadnje faze ledvične bolezni (ESRD) in celokupne smrtnosti.
60 primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Pri podrobnem proučevanju posameznih komponent primarnega izida, niso opazili učinka na celokupno smrtnost, pač pa pozitivno tendenco pri zniževanju ESRD in pomembno zmanjšanje podvojitve serumskega kreatinina.
62 Film-coating:
62 silicijev dioksid magnezijev stearat
The PSUR cycle of Irbesartan Winthrop is aligned with the cross-referred product, APROVEL, until otherwise specified.
Cikel predajanja periodičnih poročil o varnosti zdravila Irbesartan Winthrop, je vezan na referenčno zdravilo APROVEL, dokler ni določeno drugače.
Irbesartan Winthrop 75 mg tablets irbesartan
Irbesartan Winthrop 75 mg tablete irbesartan
EU/ 1/ 06/ 376/ 001 14 tablets EU/ 1/ 06/ 376/ 002 28 tablets EU/ 1/ 06/ 376/ 003 56 tablets EU/ 1/ 06/ 376/ 004 56 x 1 tablets EU/ 1/ 06/ 376/ 005 98 tablets
EU/ 1/ 06/ 376/ 001 14 tablet EU/ 1/ 06/ 376/ 002 28 tablet EU/ 1/ 06/ 376/ 003 56 tablet EU/ 1/ 06/ 376/ 004 56 x 1 tablet EU/ 1/ 06/ 376/ 005 98 tablet
Irbesartan Winthrop 150 mg tablets irbesartan
Irbesartan Winthrop 150 mg tablete irbesartan
EU/ 1/ 06/ 376/ 006 14 tablets EU/ 1/ 06/ 376/ 007 28 tablets EU/ 1/ 06/ 376/ 008 56 tablets EU/ 1/ 06/ 376/ 009 56 x 1 tablets EU/ 1/ 06/ 376/ 010 98 tablets
EU/ 1/ 06/ 376/ 006 14 tablet EU/ 1/ 06/ 376/ 007 28 tablet EU/ 1/ 06/ 376/ 008 56 tablet EU/ 1/ 06/ 376/ 009 56 x 1 tablet EU/ 1/ 06/ 376/ 010 98 tablet
Irbesartan Winthrop 300 mg tablets irbesartan
Irbesartan Winthrop 300 mg tablete irbesartan
EU/ 1/ 06/ 376/ 011 14 tablets EU/ 1/ 06/ 376/ 012 28 tablets EU/ 1/ 06/ 376/ 013 56 tablets EU/ 1/ 06/ 376/ 014 56 x 1 tablets EU/ 1/ 06/ 376/ 015 98 tablets
EU/ 1/ 06/ 376/ 011 14 tablet EU/ 1/ 06/ 376/ 012 28 tablet EU/ 1/ 06/ 376/ 013 56 tablet EU/ 1/ 06/ 376/ 014 56 x 1 tablet EU/ 1/ 06/ 376/ 015 98 tablet
Irbesartan Winthrop 75 mg film-coated tablets irbesartan
Irbesartan Winthrop 75 mg filmsko obložene tablete irbesartan
EU/ 1/ 06/ 376/ 016 14 tablets EU/ 1/ 06/ 376/ 017 28 tablets EU/ 1/ 06/ 376/ 018 56 tablets EU/ 1/ 06/ 376/ 019 56 x 1 tablets EU/ 1/ 06/ 376/ 020 84 tablets EU/ 1/ 06/ 376/ 021 98 tablets
EU/ 1/ 06/ 376/ 016 14 tablet EU/ 1/ 06/ 376/ 017 28 tablet EU/ 1/ 06/ 376/ 018 56 tablet EU/ 1/ 06/ 376/ 019 56 x 1 tablet EU/ 1/ 06/ 376/ 020 84 tablet EU/ 1/ 06/ 376/ 021 98 tablet
Irbesartan Winthrop 150 mg film-coated tablets irbesartan
Irbesartan Winthrop 150 mg filmsko obložene tablete irbesartan
EU/ 1/ 06/ 376/ 022 14 tablets EU/ 1/ 06/ 376/ 023 28 tablets EU/ 1/ 06/ 376/ 024 56 tablets EU/ 1/ 06/ 376/ 025 56 x 1 tablets EU/ 1/ 06/ 376/ 026 84 tablets EU/ 1/ 06/ 376/ 027 98 tablets
EU/ 1/ 06/ 376/ 022 14 tablet EU/ 1/ 06/ 376/ 023 28 tablet EU/ 1/ 06/ 376/ 024 56 tablet EU/ 1/ 06/ 376/ 025 56 x 1 tablet EU/ 1/ 06/ 376/ 026 84 tablet EU/ 1/ 06/ 376/ 027 98 tablet
Irbesartan Winthrop 300 mg film-coated tablets irbesartan
Irbesartan Winthrop 300 mg filmsko obložene tablete irbesartan
EU/ 1/ 06/ 376/ 028 14 tablets EU/ 1/ 06/ 376/ 029 28 tablets EU/ 1/ 06/ 376/ 030 56 tablets EU/ 1/ 06/ 376/ 031 56 x 1 tablets EU/ 1/ 06/ 376/ 032 84 tablets EU/ 1/ 06/ 376/ 033 98 tablets
EU/ 1/ 06/ 376/ 028 14 tablet EU/ 1/ 06/ 376/ 029 28 tablet EU/ 1/ 06/ 376/ 030 56 tablet EU/ 1/ 06/ 376/ 031 56 x 1 tablet EU/ 1/ 06/ 376/ 032 84 tablet EU/ 1/ 06/ 376/ 033 98 tablet
INFORMATION FOR THE USER Irbesartan Winthrop 75 mg tablets irbesartan
87 NAVODILO ZA UPORABO Irbesartan Winthrop 75 mg tablete irbesartan
What Irbesartan Winthrop is and what it is used for 2.
Kaj je zdravilo Irbesartan Winthrop in za kaj ga uporabljamo 2.
Before you take Irbesartan Winthrop 3.
Kaj morate vedeti, preden boste vzeli zdravilo Irbesartan Winthrop 3.
How to take Irbesartan Winthrop 4.
Kako jemati zdravilo Irbesartan Winthrop 4.
How to store Irbesartan Winthrop 6.
Shranjevanje zdravila Irbesartan Winthrop 6.
WHAT IRBESARTAN WINTHROP IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO IRBESARTAN WINTHROP IN ZA KAJ GA UPORABLJAMO
Irbesartan Winthrop belongs to a group of medicines known as angiotensin-II receptor antagonists.
Zdravilo Irbesartan Winthrop spada v skupino zdravil, ki so znana kot antagonisti angiotenzina- II.
Irbesartan Winthrop prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Zdravilo Irbesartan Winthrop preprečuje vezavo angiotenzina- II na te receptorje in tako sprošča krvne žile ter znižuje krvni tlak.
Irbesartan Winthrop slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 zdravilo Irbesartan Winthrop upočasni pešanje delovanja ledvic.
Irbesartan Winthrop is used to treat high blood pressure (essential hypertension) to protect the kidney in patients with high blood pressure, type 2 diabetes and laboratory evidence of impaired kidney function.
Zdravilo Irbesartan Winthrop uporabljamo: za zdravljenje povečanega krvnega tlaka (primarne hipertenzije). za zaščito ledvic pri bolnikih z visokim krvnim tlakom, ki imajo sladkorno bolezen tipa 2 in laboratorijsko potrjeno okvaro delovanja ledvic.
BEFORE YOU TAKE IRBESARTAN WINTHROP
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO IRBESARTAN WINTHROP
Do not take Irbesartan Winthrop if you are allergic (hypersensitive) to irbesartan or any other ingredients of Irbesartan Winthrop during the last 6 months of pregnancy, see section Pregnancy and breastfeeding if you are breast-feeding
Ne jemljite zdravila Irbesartan Winthrop če ste alergični na (preobčutljivi za) irbesartan ali katerokoli sestavino zdravila Irbesartan Winthrop če ste noseči že več kot tri mesece (glejte poglavje Nosečnost in dojenje) če dojite
Irbesartan Winthrop should not be given to children and adolescents (under 18 years).
Zdravila Irbesartan Winthrop ne smejo jemati otroci in mladostniki (mlajši od 18 let).
Take special care with Irbesartan Winthrop Tell your doctor if any of the following apply to you: if you get excessive vomiting or diarrhoea if you suffer from kidney problems if you suffer from heart problems if you receive Irbesartan Winthrop for diabetic kidney disease.
Bodite posebno pozorni pri jemanju zdravila Irbesartan Winthrop Obvestite svojega zdravnika, če se karkoli od naslednjega nanaša na vas: če začnete prekomerno bruhati ali dobite hudo drisko če imate težave z ledvicami če imate težave s srcem če zdravilo Irbesartan Winthrop jemljete zaradi diabetične bolezni ledvic.
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function if you are going to have an operation (surgery) or be given anaesthetics You must tell your doctor if you think that you are (or might become) pregnant.
V tem primeru bo zdravnik morda moral redno opravljati krvne preiskave, še posebej tiste, s katerimi bo v primeru slabega delovanja ledvic spremljal vrednosti kalija v krvi. če imate predvideno operacijo (kirurški poseg) ali boste dobili anestetik
Irbesartan Winthrop is not recommended in early pregnancy and may cause serious harm to your baby after 3 months of pregnancy, see section Pregnancy and breastfeeding.
Uporaba zdravila Irbesartan Winthrop ni priporočljiva v zgodnjem obdobju nosečnosti, po tretjem mesecu nosečnosti pa lahko povzroči resno škodo vašemu otroku (glejte poglavje Nosečnost in dojenje).
88 Using other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Uporaba drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Irbesartan Winthrop does not usually interact with other medicines.
Zdravilo Irbesartan Winthrop običajno ne vpliva na delovanje drugih zdravil in obratno.
Taking Irbesartan Winthrop with food and drink Irbesartan Winthrop can be taken with or without food.
Jemanje zdravila Irbesartan Winthrop skupaj s hrano in pijačo Zdravilo Irbesartan Winthrop lahko jemljete s hrano ali brez nje.
Usually, your doctor will advise you to take another medicine instead of Irbesartan Winthrop, as Irbesartan Winthrop is not recommended in early pregnancy, and may cause serious harm to your baby if it is used after 3 months of pregnancy.
Zdravnik vam bo praviloma svetoval jemanje drugega zdravila namesto zdravila Irbesartan Winthrop, saj jemanje zdravila Irbesartan Winthrop v zgodnjem obdobju nosečnosti ni priporočljivo in lahko po tretjem mesecu nosečnosti povzroči resno škodo vašemu otroku.
Appropriate antihypertensive drug must usually replace Irbesartan Winthrop before starting a pregnancy.
V primeru načrtovanja nosečnosti je treba praviloma preiti na drugo vrsto zdravljenja proti zvišanemu krvnemu tlaku.
The product should not be used during the 2nd and 3rd trimester of pregnancy, or while breast-feeding.
Zdravila Irbesartan Winthrop ne smete jemati v drugem in tretjem trimesečju nosečnosti ali če dojite.
Your doctor will normally advise you to stop taking Irbesartan Winthrop as soon as you know you are pregnant.
Zdravnik vam bo praviloma svetoval, da prekinete z jemanjem zdravila Irbesartan Winthrop takoj, ko izveste, da ste noseči.
If you become pregnant during therapy with Irbesartan Winthrop, please inform and see your doctor without delay.
Če zanosite med zdravljenjem z zdravilom Irbesartan Winthrop, takoj obvestite svojega zdravnika.
Irbesartan Winthrop is unlikely to affect your ability to drive or use machines.
Verjetnost, da bi zdravilo Irbesartan Winthrop vplivalo na sposobnost upravljanja vozil ali strojev, je majhna.
Important information about some of the ingredients of Irbesartan Winthrop Irbesartan Winthrop contains lactose.
Pomembne informacije o nekaterih sestavinah zdravila Irbesartan Winthrop Zdravilo Irbesartan Winthrop vsebuje laktozo.
HOW TO TAKE IRBESARTAN WINTHROP
KAKO JEMATI ZDRAVILO IRBESARTAN WINTHROP
Always take Irbesartan Winthrop exactly as your doctor has told you.
Pri jemanju zdravila Irbesartan Winthrop natančno upoštevajte zdravnikova navodila.
Method of administration Irbesartan Winthrop is for oral use.
Način uporabe Zdravilo Irbesartan Winthrop je potrebno zaužiti.
You can take Irbesartan Winthrop with or without food.
Zdravilo Irbesartan Winthrop lahko jemljete s hrano ali brez nje.
It is important that you continue to take Irbesartan Winthrop until your doctor tells you otherwise.
Pomembno je, da zdravilo Irbesartan Winthrop jemljete redno, vse dokler vam zdravnik ne predpiše drugače.
Patients with high blood pressure The usual dose is 150 mg once a day (two tablets a day).
89 Običajen odmerek je 150 mg enkrat na dan (dve tableti).